REG - GSK PLC - Statement: Zantac (ranitidine) litigation

GSKAnnouncement

07/12/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221207:nRSG8794Ia&default-theme=true

RNS Number : 8794I  GSK PLC  07 December 2022

Issued: 07 December 2022, London UK

 

Statement: Zantac (ranitidine) litigation

 

·   MDL Court has dismissed all cases alleging the five remaining cancers
in the MDL

·   Scientific consensus is that there is no consistent or reliable
evidence that ranitidine increases the risk of any cancer

·   GSK will continue to defend itself vigorously, including against all
claims brought at the state level in the U.S.

 

 

In response to yesterday's court ruling in the Zantac federal Multi-District
Litigation (MDL) in the U.S., GSK plc (LSE/NYSE: GSK) today issued the
following statement:

 

GSK welcomes yesterday's ruling by the MDL Court. Following the 12
epidemiological studies conducted looking at human data regarding the use of
ranitidine, the scientific consensus is that there is no consistent or
reliable evidence that ranitidine increases the risk of any cancer.
Yesterday's ruling reflects the state of that science and ensured that
unreliable and litigation-driven science did not enter the federal courtroom.

 

In excluding plaintiffs' epidemiological evidence and expert testimony based
on their deficiencies and unreliability, the Court has dismissed all MDL cases
alleging the five remaining cancers in the MDL (liver, bladder, pancreatic,
esophageal, and stomach). GSK will continue to defend itself vigorously,
including against all claims brought at the state level.

 

Further information regarding the litigation can be found in GSK's 11 August
2022 and 16 August 2022 statements, and in its third quarter results press
release issued on 2 November 2022. These are available on www.gsk.com
(http://www.gsk.com) .

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com/company
(https://www.gsk.com/en-gb/company/)

 

 GSK enquiries
 Media:               Tim Foley          +44 (0) 20 8047 5502  (London)
                      Madeleine Breckon  +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn     +1 202 603 5003       (Washington DC)
                      Lyndsay Meyer      +1 202 302 4595       (Washington DC)

 Investor Relations:  Nick Stone         +44 (0) 7717 618834   (London)
                      James Dodwell      +44 (0) 20 8047 2406  (London)
                      Mick Readey        +44 (0) 7990 339653   (London)
                      Josh Williams      +44 (0) 7385 415719   (London)
                      Jeff McLaughlin    +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco   +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described in
the Company's Annual Report on Form 20-F for 2021, GSK's Q3 Results for 2022
and any impacts of the COVID-19 pandemic.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  STRUPGUWPUPPUQM